Circulating sex steroids and breast cancer risk in premenopausal women

Hormones and Cancer

Volumn 1, Issue 1, 2010, Pages 2-10

  Hankinson, Susan E ^a   Eliassen, A Heather ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Androgens; Breast cancer; Estrogens; Premenopausal; Progesterone; Prospective

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; PRASTERONE; PRASTERONE SULFATE; PROGESTERONE; SEX HORMONE; TESTOSTERONE;

ARTICLE; BODY MASS; BODY SIZE; BREAST CANCER; BREAST FEEDING; CANCER RISK; DISEASE ASSOCIATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAMMOGRAPHY; MATERNAL AGE; MENARCHE; MENSTRUAL CYCLE; PARITY; PREMENOPAUSE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GONADAL STEROID HORMONES; HUMANS; PREMENOPAUSE; RISK FACTORS;

EID: 78650185904     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-009-0003-0     Document Type: Article

References (76)

1. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Buenode-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12 (4):1071-1082
2. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(24):1856-1865
3. Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606-616
4. Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6(5):213-218
5. Liao DJ, Dickson RB (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80(2):175-189
6. Dickson RB, Stancel GM (2000) Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 27:135-145
7. King RJ (1993) William L. McGuire memorial symposium. Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res Treat 27(1-2):3-15
8. de Waard F, Thijssen JH (2005) Hormonal aspects in the causation of human breast cancer: epidemiological hypotheses reviewed, with special reference to nutritional status and first pregnancy. J Steroid Biochem Mol Biol 97(5):451-458
9. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296-300
10. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235-3258 PMCID: PMC2716943
11. Rabaglio M, Aebi S, Castiglione-Gertsch M (2007) Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 8 (10):940-949
12. Muti P, Trevisan M, Micheli A, Krogh V, Bolelli G, Sciajno R, Berrino F (1996) Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 5(11):917-922
13. Micheli A, Muti P, Pisani P, Secreto G, Recchione C, Totis A, Fissi R, Cavalleri A, Panico S, Berrino F (1991) Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women. J Clin Epidemiol 44(10):1055-1061
14. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE (2006) Reproductibility of plasma hormone and growth factor levels among premenopausal women over a 2-3 year period. Cancer Epidemiol Biomarkers Prev 15 (5):972-978
15. Michaud DS, Manson JE, Spiegelman D, Barbieri RL, Sepkovic DW, Bradlow HL, Hankinson SE (1999) Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 8 (12):1059-1064
16. Willett WC (1998) Nutritional epidemiology, 2nd edn. Oxford University Press, New York
17. Rosner B, Spiegelman D, Willett WC (1992) Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 136(11):1400-1413
18. Mady EA, Ramadan EE, Ossman AA (2000) Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers 16(3-4):151-157
19. Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1-3):31-41
20. Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21(3):427-433
21. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203-232
22. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270-282
23. Van Aswegen CH, Purdy RH, Wittliff JL (1989) Binding of 2hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 32(4):485-492
24. Anstead GM, Carlson KE, Katzenellenbogen JA (1997) The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62(3):268-303
25. Barnea ER, MacLusky NJ, Naftolin F (1983) Kinetics of catechol estrogen-estrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity. Steroids 41(5):643-656
26. Miyairi S, Ichikawa T, Nambara T (1991) Structure of the adduct of 16 alpha-hydroxyestrone with a primary amine: evidence for the Heyns rearrangement of steroidal D-ring alpha-hydroxyimines. Steroids 56(7):361-366
27. Bucala R, Fishman J, Cerami A (1982) Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci USA 79 (10):3320-3324
28. Swaneck GE, Fishman J (1988) Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 85(21):7831-7835
29. Lustig RH, Mobbs CV, Pfaff DW, Fishman J (1989) Temporal actions of 16 alpha-hydroxyestrone in the rat: comparisons of lordosis dynamics with other estrogen metabolites and between sexes. J Steroid Biochem 33(3):417-421
30. Seeger H, Wallwiener D, Kraemer E, Mueck AO (2005) Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 54:72-77
31. Gupta M, McDougal A, Safe S (1998) Estrogenic and antiestrogenic activities of 16alphaand 2-hydroxy metabolites of 17betaestradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol 67(5-6):413-419
32. Schneider J, Huh MM, Bradlow HL, Fishman J (1984) Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259(8):4840-4845
33. Vandewalle B, Lefebvre J (1989) Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 61(2):239-246
34. Mueck AO, Seeger H, Lippert TH (2002) Estradiol metabolism and malignant disease. Maturitas 43(1):1-10
35. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG (1997) Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94(20):10937-10942
36. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL (1996) Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 9 (5):851-859
37. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86(3-5):477-486
38. Devanesan P, Todorovic R, Zhao J, Gross ML, Rogan EG, Cavalieri EL (2001) Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: potential biomarkers for estrogen-initiated cancer. Carcinogenesis 22(3):489-497
39. Chakravarti D, Mailander PC, Li KM, Higginbotham S, Zhang HL, Gross ML, Meza JL, Cavalieri EL, Rogan EG (2001) Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 20(55):7945-7953
40. Cavalieri EL, Kumar S, Todorovic R, Higginbotham S, Badawi AF, Rogan EG (2001) Imbalance of estrogen homeostasis in kidney and liver of hamsters treated with estradiol: implications for estrogen-induced initiation of renal tumors. Chem Res Toxicol 14(8):1041-1050
41. Wysowski DK, Comstock GW, Helsing KJ, Lau HL (1987) Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 125(5):791-799
42. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW (1994) A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 18(2):79-85
43. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE (2000) A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 9(6):575-579
44. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 75(7):1075-1079
45. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG (1994) Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 140(6):518-525
46. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjonneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97(10):755-765
47. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406-1415
48. Siiteri PK (1981) Extraglandular oestrogen formation and serum binding of oestradiol: relationship to cancer. J Endocrinol 89 (Suppl):119P-129P
49. Siiteri PK, MacDonald PC (1973) The role of extraglandular estrogen in human endocrinology. In: Geiger SR, Astwood EB, Greep RO (eds) Handbook of physiology: section 7-Endocrinology 615-629. American Physiological Society, New York
50. Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, Gold EB, Finkelstein JS, Greendale GA, Kelsey J, Korenman S, Luborsky JL, Matthews K, Midgley R, Powell L, Sabatine J, Schocken M, Sowers MF, Weiss G (2004) Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: the Study of Women's Health across the Nation (SWAN) Daily Hormone Study. J Clin Endocrinol Metab 89(6):2622-2631
51. Landgren BM, Collins A, Csemiczky G, Burger HG, Baksheev L, Robertson DM (2004) Menopause transition: annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 89(6):2763-2769
52. Yue W, Santner SJ, Masamura S, Wang JP, Demers LM, Hamilton C, Santen RJ (1998) Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 49(Suppl 1):S1-S7, discussion S33-7
53. Masamura S, Santner SJ, Gimotty P, George J, Santen RJ (1997) Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 42(3):215-226
54. Stute P, Wood CE, Kaplan JR, Cline JM (2004) Cyclic changes in the mammary gland of cynomolgus macaques. Fertil Steril 82 (Suppl 3):1160-1170
55. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH (1998) Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 78(9):1250-1255
56. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F (2000) Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16 alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11 (6):635-640
57. Arslan AA, Shore RE, Afanasyeva Y, Koenig KL, Toniolo P, Zeleniuch-Jacquotte A (2009) Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 18(8):2273-2279
58. Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, Saavedra JE, Keefer LK, Ziegler RG (2005) Measuring fifteen endogenous estrogens simultaneously in human urine by high performance liquid chromatography-mass spectrometry. Anal Chem 77(20):6646-6654
59. Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG (2008) A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev 17(12):3411-3418
60. Eliassen HA, Ziegler RG, Rosner B, Veenstra TD, Roman JM, Xu X, Hankinson SE (2009) Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2 to 3-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 18(11):2860
61. Ebeling P, Koivisto VA (1994) Physiological importance of dehydroepiandrosterone. Lancet 343(8911):1479-1481
62. Seymour-Munn K, Adams J (1983) Estrogenic effects of 5-androstene-3 beta, 17 beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology 112(2):486-491
63. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F (2004) Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 112(2):312-318
64. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90(1):153-159
65. Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW (1992) Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 52(1):1-4
66. Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE (2004) Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 13(6):1032-1036
67. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE (2006) The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 15(5):967-971
68. Mauvais-Jarvis P, Kuttenn F, Gompel A (1987) Antiestrogen action of progesterone in breast tissue. Horm Res 28(2-4):212-218
69. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10 (2):179-186
70. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17-35
71. Lanari C, Molinolo AA (2002) Progesterone receptors-animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res 4(6):240-243
72. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F (2005) Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 96(2):95-108
73. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350(9084):1047-1059
74. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101(7):1490-1500
75. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14):1701-1712
76. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289(24):3243-3253